SignaGen’s LentiMAX™ Packaging System is a core platform for cell therapy research, optimized for high-titer production of chimeric antigen receptor (CAR) lentiviral vectors. It supports efficient packaging of large and complex CAR constructs, including those with cytotoxic elements that are challenging for conventional systems. Our technical team provides tailored vector design and production strategies to preserve viral yield and transgene stability for demanding immunotherapy applications.

We collaborate with academic institutions and pharmaceutical partners worldwide to develop customized CAR expression vectors aligned with specific therapeutic targets and research goals.

Among viral platforms, lentivirus remains the gold standard for CAR-T manufacturing due to its ability to stably integrate the CAR transgene, ensuring durable expression during ex vivo expansion. AAV is being explored for in vivo CAR-T approaches but is limited by packaging capacity, while adenovirus is primarily used as an immunomodulatory tool to enhance CAR-T efficacy rather than for direct cell engineering.

---

Key Practical Differences

Persistence:
Because activated T cells undergo rapid proliferation upon antigen engagement, the non-integrating nature of AdV and AAV leads to progressive dilution or loss of CAR expression over time. This limitation is a primary reason lentiviral vectors remain the preferred choice for achieving durable CAR expression and long-term clinical remission.

Safety:
AAV is generally considered safer for systemic in vivo applications than adenovirus due to its substantially reduced activation of innate immune responses and lower risk of inducing acute cytokine release syndromes.

Payload Capacity:
Advanced fourth-generation (“armored”) CAR-T constructs—incorporating inducible cytokines, safety switches, or additional regulatory modules—often exceed the packaging constraints of AAV. In these cases, lentivirus or adenovirus provides greater design flexibility due to their larger genome capacities.

---